Drugs / Bone Marrow cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02638467 | Nov 2015 → Nov 2018 | Philadelphia-positive myelogenous leukemia | University of Milano Bicocca | Completed | No outcome recorded |
| Phase 2 | NCT01459107 | Jul 2011 → Jun 2036 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone Marrow cells | “Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host...” NCT01459107 ↗ |
| Modality | Cell therapy | “This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA)” NCT01459107 ↗ |